SANA

Over the past six months, Sana Biotechnology's stock decreased by 14.60% in the past month and by 5.78% over the last 12 months, with a year-to-date return of -23.83%, trading at $3.10 with a market capitalization of $928.02 million as of September 17, 2026. Notable events include presentations at several investor conferences in September 2026, reporting Second Quarter 2026 Financial Results in August 2026, and a follow-on publication in The New England Journal of Medicine in July 2026 highlighting long-term data for hypoimmune-modified islet cell transplantation. The August 2025 pivot to CDMOs and the pause of the Bothell facility build-out led to a $44.6 million impairment charge and a net loss of $93.6 million for the quarter. A major risk was identified in August 2026, indicating less than a year of cash runway.